---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-016711"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:26:08.829467+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents raises $1.6M from Series A warrant exercises; total rights offering proceeds $7.85M

## Summary
- 1,417,208 Series A Right Warrants exercised at $1.13 each for $1.6M gross proceeds upon expiration.
- Total rights offering gross proceeds reached $7.85M; net liquidity increased by ~$12.3M after restricted cash released.
- Approximately 4.8M shares remain reserved for Series B Right Warrants, exercisable until April 10, 2025.
- CEO notes progress on DrugSorb-ATR regulatory applications with U.S. FDA and Health Canada, expecting decisions in 2025.

## SEC filing metadata
- accession: 0001104659-25-016711
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465925016711/0001104659-25-016711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465925016711/tm257523d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-016711
- JSON: https://secwatch.observer/filing/0001104659-25-016711.json
- Plain text: https://secwatch.observer/filing/0001104659-25-016711.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.